REPATRIATION MEDICAL AUTHORITY

INSTRUMENT NO. 18 of 2012

VETERANS’ ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

EXPLANATORY NOTES FOR TABLING

1. The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans’ Entitlements Act 1986 (the VEA), revokes Instrument No. 20 of 2000, determined under subsection 196B(3) of the VEA concerning chloracne.

2.             The Authority is of the view that on the sound medical-scientific evidence available it is more probable than not that chloracne and death from chloracne can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(3) of the VEA a Statement of Principles, Instrument No. 18 of 2012 concerning chloracne.  This Instrument will in effect replace the revoked Statement of Principles.

3.             The provisions of the Military Rehabilitation and Compensation Act 2004 (the MRCA) relating to claims for compensation commenced on 1 July 2004.  Claims under section 319 of the MRCA for acceptance of liability for a service injury sustained, a service disease contracted or service death on or after 1 July 2004 are determined by the Military Rehabilitation and Compensation Commission by reference to Statements of Principles issued by the Authority pursuant to the VEA.

4.             The Statement of Principles sets out the factors that must exist, and which of those factors must be related to the following kinds of service rendered by a person:

 eligible war service (other than operational service) under the VEA;

 defence service (other than hazardous service and British nuclear test defence service) under the VEA;

 peacetime service under the MRCA,

before it can be said that, on the balance of probabilities, chloracne or death from chloracne is connected with the circumstances of that service.

5.             This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 30 June 2010 concerning chloracne in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

6.             The contents of this Instrument are in similar terms as the revoked Instrument.  Comparing this Instrument and the revoked Instrument, the differences include:

• adopting the latest revised Instrument format, which commenced in 2005;
• deleting the ICD code from the Instrument header;
• revising the definition of 'chloracne' in clause 3;
• revising factor 6(a) concerning 'inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon';
• new factors 6(b) & 6(f) concerning 'inhaling, ingesting or having cutaneous contact with a polychlorodibenzofuran (PCDF) from the specified list';
• new factors 6(c) & 6(g) concerning 'inhaling, ingesting or having cutaneous contact with a polychlorodibenzo-para-dioxin (PCDD) from the specified list';
• new factors 6(d) & 6(h) concerning 'inhaling, ingesting or having cutaneous contact with a specified chemical agent, during the manufacture of which 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD), another polychlorodibenzo-para-dioxin (PCDD) or a polychlorodibenzofuran (PCDF) is generated';
• new factor 6(e) concerning 'inhaling, ingesting or having cutaneous contact with a polyhalogenated aromatic hydrocarbon' for clinical worsening;
• deleting the factor concerning 'being exposed to halogenated organochlorine compounds or halogenated organobromine compounds' as it is now covered by other factors;
• new definitions of 'a polychlorodibenzofuran (PCDF) from the specified list', 'a polychlorodibenzo-para-dioxin (PCDD) from the specified list', 'a polyhalogenated aromatic hydrocarbon from the specified list', 'a specified chemical agent' and 'inhaling, ingesting or having cutaneous contact with' in clause 9;
• revising the definition of 'relevant service' in clause 9;
• deleting definitions of 'halogenated organochlorine compounds', 'halogenated organobromine compounds' and 'ICD-10-AM code'; and
• specifying a date of effect for the Instrument in clause 11.

7.             Further changes to the format of the Instrument reflect the commencement of the MRCA and clarify that pursuant to subsection 196B(3A) of the VEA, the Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

8.             Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to chloracne in the Government Notices Gazette of 30 June 2010, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  No submissions were received for consideration by the Authority during the investigation.

9.             This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny Act 2011).

10.         The determining of this Instrument finalises the investigation in relation to chloracne as advertised in the Government Notices Gazette of 30 June 2010.

11.         A list of references relating to the above condition is available to any person or organisation referred to in subsection 196E(1)(a) to (c) of the VEA.  Any such request must be made in writing to the Repatriation Medical Authority at the following address:

The Registrar

Repatriation Medical Authority Secretariat

GPO Box 1014

BRISBANE    QLD    4001